UNSPSC 51393408: Acefylline

This classification denotes a bronchodilator with the molecular structure C9H10N4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, M494UE2YEP chemically known as 1,2,3,6-tetrahydro-1,3-dimethyl-2,6-dioxopurine-7-acetic a but generally known as acefylline, which bears US NIH Compound Identifier 69550. European Medicines Agency schedules Acefylline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00243MIG.

The term ACEFYLLINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 35, no. 5 1981, list 21). As of Q4 2014, ACEFYLLINE remains the US FDA Preferred Term for this commodity. Acefylline bears US NLM identifiers UMLS ID C0050405 and NCI Concept Code C96200. SMILES: CN1C2=C(C(=O)N(C1=O)C)N(C=N2)CC(=O)O.

UNSPSC 51393408 Acefylline, a Commodity code, shows limited alignment with the recent state and local procurement activity tagged under it. The single recent opportunity posted under this code is Seminole County, Florida's IFB 60459723LAS, which solicits naloxone and safe drug deactivation systems—pharmaceutical and medical devices for opioid overdose response and controlled substance disposal—rather than acefylline, a bronchodilator pharmaceutical. The mismatch suggests either a data-classification anomaly or a broad tagging error rather than active market demand for acefylline itself within state and local procurement channels.

Seminole County Community Health's naloxone and drug deactivation procurement, due July 26, 2023, is the sole recent solicitation visible under this code and does not support a broader pattern of acefylline purchasing across state and local jurisdictions. The sourcing body is a county health authority seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries. Without additional recent opportunities tagged to this code across other states or issuing bodies, the Commodity code appears dormant for acefylline-specific procurement in state and local markets as of October 2026.